Elimusertib (formerly known as BAY-1895344) is a highly selective and orally bioavailable inhibitor of ATR (ataxia telangiectasia and Rad3-related) with potential anticancer activity. It inhibits ATR with an IC50 value of 7 nM. BAY 1895344 shows potent anti-proliferative activity in vitro against a broad spectrum of human cancer cell lines with an IC50 of 78 […]
HAMNO (formerly known as NSC-111847) is a novel, potent and selective protein interaction inhibitor of replication protein A (RPA).
Elimusertib (BAY1895344) diHCl, the dihydrochloride salt of BAY 1895344, is a potent, selective and orally bioavailable ATR (ataxia telangiectasia and Rad3-related) inhibitor with potential antineoplastic activity.
Chloroquine phosphate is reported to be highly effective in combating SARS-CoV-2 (COVID-19, CoronaVirus, or the COVID-19 pandemic) infection in vitro.
VE-821 is a novel potent and highly selective ATP competitive protein kinase inhibitor of ATR (ataxia telangiectasia mutated and Rad3 related) with Ki and IC50 of 13 nM and 26 nM in cell-free assays, it shows inhibition of H2AX phosphorylation, and had minimal activity against PIKKs ATM, DNA-PK, mTOR and PI3Kγ.
AZD1390 (AZD-1390) is a novel, potent, selective, first-in-class orally bioavailable and CNS penetrant inhibitor of Ataxia-telangiectasia mutated (ATM) kinase with potential anticancer activity.
CP-466722 is a novel, specific and reversible ATM inhibitor with an IC50 value of 4.1 μM, it does not affect ATR and inhibits PI3K or PIKK family members in cells.
Elimusertib (BAY1895344) HCl, the hydrochloride salt of BAY 1895344, is a selective and orally bioavailable ATR (ataxia telangiectasia and Rad3-related) inhibitor with potential antitumor activity.
KU-60019 is an improved analogue of KU-55933 with 10-fold higher activity than KU-55933 at blocking radiation-induced phosphorylation of key ATM targets in human glioma cells.
This product is discontinued due to commercial reason,Berzosertib (VE-822; VX-970; M6620) is a specific ATR inhibitor with IC50 of 19 nM in HT29 cells. VE-822 inhibited ATR in vitro and in vivo. VE-822 decreased maintenance of cell-cycle checkpoints, increased persistent DNA damage and decreased homologous recombination in irradiated cancer cells. VE-822 decreased survival of pancreatic […]